• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

GSK Stock drops









Pfizer, Johnson & Johnson, Merck, Lilly, Roche, and Novartis on average have seen stock price increases in the range of 100% to 200% over the last ten years. Contrast that to GSK who's stock price has increased by approximately 10-15% over the decade.
Who would you put your money with?
 




Pfizer, Johnson & Johnson, Merck, Lilly, Roche, and Novartis on average have seen stock price increases in the range of 100% to 200% over the last ten years. Contrast that to GSK who's stock price has increased by approximately 10-15% over the decade.
Who would you put your money with?